Treatment Category Profile

Treatment Name:	monoclonal antibody g250	Known as: Also Known As:	g250
Treatment Type:	Immunotherapy	Status:	Unknown
G250 is a tumor associated antigen (TAA) that is highly expressed on clear-cell RCC. Monoclonal antibodies to G250 are being explored as an investigational approach to treat metastatic disease. The advantage of monoclonal antibodies is their specificity for the targeted cancer cells.

   Articles related to this Treatment

1 Antibodies against RCC Wilex Homepage No Date Available 2 Heterogeneous Expression of G250 Tumor-Associated Antigen (TAA) in Renal Cell Carcinoma (RCC). ASCO Online No Date Available 3 Chimeric G250 (cG250) Monoclonal Antibody Phase I Dose Escalation Trial in Patients with Advanced Renal Cell Carcinoma (RCC). ASCO Online Jan 1, 2001 4 Monoclonal Antibodies May Be Used to Treat Kidney Cancer Oncology News Sep 1, 1999 5 Wilex Licences Antibody for Renal Cancer Wilex Homepage Aug 31, 1999 6 Phase I/II Radioimmunotherapy Trial with Iodine-131-labeled Monoclonal Antibody G250 in Metastatic Renal Cell Carcinoma American Association for Cancer Research May 7, 1998